Xyz future or investigational therapies: Difference between revisions

	Xyz Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Xyz future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Xyz future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Xyz future or investigational therapies
CDC on Xyz future or investigational therapies
Xyz future or investigational therapies in the news
Blogs on Xyz future or investigational therapies
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Xyz future or investigational therapies

Latest revision as of 13:17, 20 April 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Xyz}}
 {{CMG}}; {{AE}}
 ==Overview==
 ==Future or Investigational Therapies==
-* MCTD involves milder disease activity than systemic sclerosis and systemic lupus erythematosus. However mortality rates have been reported to be high in MCTD and it is known that organ damage increase over time even though disease activity decreases. Organ damage over time in patients with MCTD should be assessed further in future studies.
 ==References==